Page last updated: 2024-08-23

pimonidazole and mk 2206

pimonidazole has been researched along with mk 2206 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bussink, J; Grénman, R; Iida, M; Kaanders, JH; Span, PN; Stegeman, H; van der Kogel, AJ; Verheijen, MM; Waaijer, SJ; Wheeler, DL	1

Other Studies

1 other study(ies) available for pimonidazole and mk 2206

Article	Year
Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neck. BMC cancer, 2012, Oct-10, Volume: 12 Topics: Animals; Blotting, Western; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; ErbB Receptors; Fluorescent Antibody Technique; Head and Neck Neoplasms; Heterocyclic Compounds, 3-Ring; Humans; Hypoxia; Mice; Mice, Inbred BALB C; Mice, Nude; Nitroimidazoles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Radiation-Sensitizing Agents; Radiotherapy; Receptor, ErbB-2; Signal Transduction; Tumor Microenvironment; Xenograft Model Antitumor Assays	2012

Article

Year

Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neck.

BMC cancer, 2012, Oct-10, Volume: 12

Topics: Animals; Blotting, Western; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; ErbB Receptors; Fluorescent Antibody Technique; Head and Neck Neoplasms; Heterocyclic Compounds, 3-Ring; Humans; Hypoxia; Mice; Mice, Inbred BALB C; Mice, Nude; Nitroimidazoles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Radiation-Sensitizing Agents; Radiotherapy; Receptor, ErbB-2; Signal Transduction; Tumor Microenvironment; Xenograft Model Antitumor Assays

2012